Zum Inhalt springen
Foto: Pexels.com

AI tool predicts how cancer patients will respond to immunotherapy

In a proof-of-concept study, researchers at the National Institutes of Health (NIH) have developed an artificial intelligence (AI) tool that uses routine clinical data, such as that from a simple blood test, to predict whether someone’s cancer will respond to immune checkpoint inhibitors, a type of immunotherapy drug that helps immune cells kill cancer cells. The machine-learning model may help doctors determine if immunotherapy drugs are effective for treating a patient’s cancer. The study, published June 3, 2024, in Nature Cancer, was led by researchers at the National Cancer Institute’s (NCI) Center for Cancer Research and Memorial Sloan Kettering Cancer Center in New York. NCI is part of the National Institutes of Health. Currently, two predictive biomarkers are approved by the Food and Drug Administration for use in identifying patients who may be candidates for treatment with immune checkpoint inhibitors.… 

more »AI tool predicts how cancer patients will respond to immunotherapy

Immunofoco Biotech to Unveil Solid Tumor CAR-T Programs Clinical Trial Data

On June 1st, 2024, Immunofoco Biotech, a company dedicated to developing cell therapy products for solid tumors, announced that the clinical research data for two of its products have been accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The company will showcase the latest clinical trial findings for IMC001 in a poster presentation and for IMC002 in an online presentation during the ASCO event, scheduled from May 31 to June 4, 2024.

Prostate Cancer: Promising Therapy Candidate

TLX591 is an investigational anti-PSMA[1] radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen.Reported median radiographic progression-free survival (rPFS) is 8.8 months.Builds on prior data from the ProstACT SELECT[2] trial, demonstrating favourable safety profile and biodistribution[3]. The study has reported a median rPFS of 8.8 months, representing an encouraging signal of the potential efficacy of TLX591 in this patient population. The evaluable sample size for rPFS comprised 23 patients with previously treated, progressive mCRPC and who received two 76 mCi intravenous (IV) infusions of TLX591, 14 days apart[5]. The SELECT trial included a heterogeneous population of low, medium and high disease burden patients to facilitate imaging cross-comparison, with the majority having undergone two prior lines of therapy. TLX591 is being further evaluated in the Phase III ProstACT GLOBAL trial in first… 

more »Prostate Cancer: Promising Therapy Candidate

First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it is entitled to receive a milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN) triggered by the dosing of the first patient in a Phase 3 trial evaluating rilvegostomig, AstraZeneca’s PD-1/TIGIT bispecific antibody. The TIGIT component of rilvegostomig is derived from Compugen’s clinical-stage anti-TIGIT antibody, COM902. Both rilvegostomig and COM902 are designed to have reduced Fc effector function. The trial, called TROPION-Lung10, is evaluating the efficacy and safety of rilvegostomig as monotherapy and in combination with datopotamab deruxtecan (Dato-DXd), AstraZeneca and Daiichi Sankyo’s (TSE: 4568) TROP2-directed antibody drug conjugate versus pembrolizumab as first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with high PD-L1 expression (TC ? 50%) and without actionable genomic alterations. The trial is sponsored… 

more »First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

Cancer Check Labs Detects Whole Tumor Cells In Cancer Patients As Early as Stage 0

In collaboration with Comprehensive Blood & Cancer Center, Cancer Check Labs is the first to demonstrate the ability to detect and produce images of whole circulating tumor cells (CTCs) in stage 0 and stage 1 breast cancer patients. Detailed in a new white paper, Cancer Check Labs has successfully produced whole images of CTCs from the blood of several breast cancer patients, which comprised tangible cellular tissue that can be placed on a glass slide for visual inspection by a board-certified pathologist. Upon examination, a board-certified pathology report that conforms with established standard of care protocols is issued to the customers. Further, because the research has shown CTCs to be detected as early as Stage 0, Cancer Check arguably provides the earliest cancer detection test available. Among the many implications of CTC detection is the potential for providing invaluable information… 

more »Cancer Check Labs Detects Whole Tumor Cells In Cancer Patients As Early as Stage 0

Probiotika als HIV-Vakzin

Nikolai Scherbak, Dozent für Biologie an der Universität Örebro, ist gerade von einer Konferenz in Südafrika nach Schweden zurückgekehrt. Dort stellte er eine Studie vor, die die Chancen auf die Entwicklung eines Impfstoffs gegen HIV erhöht. Gemeinsam mit anderen Forschern hat er probiotische E. coli-Bakterien mit einem Teil des HIV-Virus genetisch verändert. „Mithilfe modernster Technologie fügen wir DNA-Sequenzen an einer bestimmten Stelle in das Bakterium ein. Wir verwenden einen Teil des HIV-Virus, der nicht infektiös ist, aber dennoch die Produktion neutralisierender Antikörper im Körper auslöst“, sagt Scherbak. E. coli-Bakterien leben im Darm von Menschen und anderen Tieren, und einige Varianten verursachen verschiedene Arten von Infektionen. Es gibt jedoch auch nützliche Varianten der Bakterien, die zu einer besseren Darmflora beitragen können. Eine davon, ein probiotisches E. coli-Bakterium des Stammes Nissle, wurde von den Forschern aus Örebro in der Studie verwendet. „Die… 

more »Probiotika als HIV-Vakzin

Milch kann Vogelgrippe-Virus übertragen

Mäuse, denen Rohmilchproben von Milchkühen verabreicht wurden, die mit der Grippe H5N1 infiziert waren, wiesen hohe Viruskonzentrationen in ihren Atmungsorganen und niedrigere Viruskonzentrationen in anderen lebenswichtigen Organen auf. Dies geht aus den im New England Journal of Medicine veröffentlichten Ergebnissen hervor. Die Ergebnisse legen nahe, dass der Verzehr von Rohmilch bei Tieren ein Risiko für eine H5N1-Infektion darstellt, und werfen Fragen zu diesem potenziellen Risiko für Menschen auf. Seit 2003 sind H5N1-Grippeviren in 23 Ländern im Umlauf und befallen vor allem Wildvögel und Geflügel. Etwa 900 Fälle beim Menschen sind bekannt, vor allem bei Menschen, die engen Kontakt mit infizierten Vögeln hatten. In den letzten Jahren hat sich jedoch ein hochpathogenes Vogelgrippevirus namens HPAI H5N1 ausgebreitet und mehr als 50 Tierarten infiziert. Ende März meldeten die USA einen Virusausbruch unter Milchkühen in Texas. Bisher sind 52 Rinderherden in neun Bundesstaaten… 

more »Milch kann Vogelgrippe-Virus übertragen

Novartis presents latest Phase III Fabhalta® (iptacopan) data

Novartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session of the European Renal Association (ERA) Congress1. Patients treated with Fabhalta in addition to supportive care achieved a 35.1% (p=0.0014) reduction in proteinuria (as measured by 24-hour urine protein to creatinine ratio [UPCR]) at 6 months when compared to placebo on top of supportive care1. In many kidney diseases, proteinuria reduction is an increasingly recognized surrogate marker correlating with delaying progression to kidney failure. Fabhalta is an oral Factor B inhibitor of the alternative complement pathway being investigated in adult patients with C3 glomerulopathy (C3G)1-3. Regulatory submissions, including to the FDA and EMA, for the adult C3G indication are planned for the second half of 2024. 


Novartis presents latest Phase III Fabhalta® (iptacopan) data

Novartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session of the European Renal Association (ERA) Congress1. Patients treated with Fabhalta in addition to supportive care achieved a 35.1% (p=0.0014) reduction in proteinuria (as measured by 24-hour urine protein to creatinine ratio [UPCR]) at 6 months when compared to placebo on top of supportive care1. In many kidney diseases, proteinuria reduction is an increasingly recognized surrogate marker correlating with delaying progression to kidney failure. Fabhalta is an oral Factor B inhibitor of the alternative complement pathway being investigated in adult patients with C3 glomerulopathy (C3G)1-3. Regulatory submissions, including to the FDA and EMA, for the adult C3G indication are planned for the second half of 2024. 

Krebsrisiken anhand nationaler Gesundheitsdaten berechenbar

Die Forscher trainierten zunächst ein Vorhersagemodell anhand der Daten von 6,7 Millionen erwachsenen Dänen aus den Jahren 1995 bis 2014. Der Trainingsdatensatz umfasste mehr als 1.000 verschiedene Vordiagnosen, sowie Krebserkrankungen bei Familienmitgliedern, Alter und – sofern vorhanden – grundlegende Körperdaten und Risikofaktoren wie Tabakkonsum oder Fettleibigkeit. Anschließend wurde das Modell anhand der Datensätze von 2015 bis 2018 validiert, die 4,7 Millionen Dänen umfassten, und lieferte eine hohe Vorhersagegenauigkeit. Das Modell ermöglicht Vorhersagen über die individuellen Risiken, an 20 verschiedenen Krebsarten zu erkranken. Im Laufe eines Lebens erreichte das Modell eine Genauigkeit von 81 Prozent. Unter Berücksichtigung von Alters- und Geschlechtseffekten betrug die Genauigkeit 59 Prozent. Die höchste Genauigkeit erreichte das Modell bei Krebserkrankungen des Verdauungssystems sowie bei Schilddrüsen-, Nieren- und Gebärmutterkrebs. https://www.thelancet.com/journals/landig/article/PIIS2589-7500(24)00062-1/fulltext